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Abstract  COPD  is  one  of  the  major  public  health  problems  in  people  aged  40  years  or  above.  It
is currently  the  4th  leading  cause  of  death  in  the  world  and  projected  to  be  the  3rd  leading  cause
of death  by  2020.  COPD  and  cardiac  comorbidities  are  frequently  associated.  They  share  com-
mon risk  factors,  pathophysiological  processes,  signs  and  symptoms,  and  act  synergistically  as
negative  prognostic  factors.  Cardiac  disease  includes  a  broad  spectrum  of  entities  with  distinct
pathophysiology,  treatment  and  prognosis.  From  an  epidemiological  point  of  view,  patients  with
COPD are  particularly  vulnerable  to  cardiac  disease.  Indeed,  mortality  due  to  cardiac  disease  in
patients  with  moderate  COPD  is  higher  than  mortality  related  to  respiratory  failure.  Guidelines
reinforce  that  the  control  of  comorbidities  in  COPD  has  a  clear  beneﬁt  over  the  potential  risk
associated with  the  majority  of  the  drugs  utilized.  On  the  other  hand,  the  true  survival  beneﬁts
of aggressive  treatment  of  cardiac  disease  and  COPD  in  patients  with  both  conditions  have  still
not been  clariﬁed.  Given  their  relevance  in  terms  of  prevalence  and  prognosis,  we  will  focus  in
this paper  on  the  management  of  COPD  patients  with  ischemic  coronary  disease,  heart  failure
and dysrhythmia.
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hronic  diseases  represent  the  main  cause  of  premature
eath  in  adults  worldwide.1 Chronic  respiratory  diseases
n  particular,  such  as  asthma  and  chronic  obstructive  pul-
onary  disease  (COPD),  were  directly  responsible  for  over
 million  deaths  in  2002  and  affect  hundreds  of  millions
ore.1,2
COPD  is  one  of  the  major  public  health  problems  in  people
ged  40  years  or  more.3,4 It  is  currently  the  4th  leading  cause
f  death  in  the  world  and  projected  to  be  the  3rd  leading
ause  of  death  by  2020.2 On  the  other  hand,  according  to
ome  authors,  it  is  the  leading  cause  of  chronic  morbidity
nd  mortality,  and  it  is  predicted  to  be  in  7th  place  on  the
ist  of  world  disease  burden  in  2030.1,2
COPD  and  cardiac  comorbidities  are  frequently  associ-
ted.  They  share  common  risk  factors,  pathophysiological
rocesses,  clinical  signs  and  symptoms,  and  act  syn-
rgistically  as  negative  prognostic  factors.5--7 Pulmonary
ypertension,  right  ventricular  dysfunction,  dysrhythmia
nd  ischemic  coronary  disease  are  known  consequences  of
OPD  progression.8 More  recently,  it  has  been  demonstrated
hat,  in  patients  with  COPD,  left  ventricular  dysfunction
as  a  negative  impact  on  exercise  tolerance,  being  associ-
ted  with  anxiety  and  depression,  reduced  carbon  monoxide
CO)  diffusion  and  higher  prevalence  of  right  ventricular
ysfunction.9 Similarly,  the  physical  activity  impairment
mposed  by  each  of  the  above  mentioned  pathologies  wors-
ns  the  others  and  limits  quality  of  life.10
Patients  with  COPD  are  particularly  vulnerable  to  car-
iac  disease,  with  a  higher  incidence  and  prevalence  (age
nd  gender-adjusted)  when  compared  with  patients  without
OPD.  Indeed,  mortality  due  to  cardiac  disease  in  patients
ith  moderate  COPD  is  higher  than  mortality  attributed  to
auses  related  with  respiratory  failure.7,11--15
Even  in  the  general  population,  immediately  after  acute
espiratory  infections,  a  high-risk  time  period  for  cardiovas-
ular  events  has  been  described.16 The  same  is  true  after
cute  exacerbations  in  COPD  patients,17 and  a  higher  fre-
uency  of  COPD  exacerbations  has  been  associated  with  a
igher  incidence  of  myocardial  infarction.18 In  addition,  car-
iac  biomarkers  such  as  C-reactive  Protein  (CRP),  ﬁbrinogen,
rain-type  Natriuretic  Peptide  (BNP),  N-terminal  proBNP
NT-proBNP),  troponin,  and  Vascular  Endothelial  Growth
actor  (VEGF)  are  higher  in  patients  with  COPD  exacerba-
ions  and  these  are  independent  risk  factors  for  mortality.19
COPD  prevalence  in  patients  with  heart  failure  (HF)  varies
etween  11%  and  52%  in  the  USA  and  between  9%  and  41%  in
urope,5 while  the  prevalence  of  cardiac  disease  in  patients
ith  COPD  varies  between  14%  and  33%.9,20 The  vulnerabil-
ty  to  and  impact  of  cardiac  disease  in  patients  with  COPD
s  recognized  and  has  been  implicit  in  the  guidelines  since
013.21 However,  neither  the  management  of  cardiovascu-
ar  disease  (CVD)  nor  assessment  of  cardiovascular  risk  in
atients  with  COPD  has  been  studied  well.22
The  traditionally  established  and  disseminated  fear  of
eta2-agonist  use  in  patients  with  cardiac  disturbances
nd  of  beta-blocker  (BB)  use  in  patients  with  respiratoryPlease  cite  this  article  in  press  as:  André  S,  et  al.  Pulmonol.  20
iseases  is  one  of  the  reasons  underlying  suboptimal  treat-
ent  of  both  conditions  when  they  coexist,  as  opposed
o  patients  with  isolated  COPD  or  CVD.  Current  guidelines
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einforce  the  idea  that  the  control  of  comorbidities  has  a
lear  beneﬁt  over  the  potential  risks  associated  with  the
se  of  these  drugs  and  there  is  no  clear  evidence  sustaining
hese  fears.5--7,10,23 For  example,  Mesquita  et  al  conducted
 research  study  involving  COPD  patients  with  and  without
mpaired  left  ventricular  ejection  fraction  (LVEF)  and  found
hat  only  half  of  the  cohort  with  impaired  LVEF  was  under
argeted  therapy  for  heart  failure.9
On  the  other  hand,  the  true  survival  beneﬁts  of  aggressive
reatment  of  cardiac  disease  and  COPD  in  patients  with  both
onditions  are  still  not  clariﬁed.2 Cardiac  disease  includes
 broad  spectrum  of  entities  with  distinct  pathophysiology,
reatment  and  prognosis.  Given  their  relevance  in  terms  of
revalence  and  prognosis,  we  will  focus  in  this  paper  on
he  management  of  COPD  patients  with  ischemic  coronary
isease,  heart  failure  and  dysrhythmia.
athophysiology of COPD and Cardiovascular
isease
ardiovascular  disease  and  COPD
OPD  is  a  chronic  pulmonary  disease  with  an  often  indo-
ent  evolution  and  systemic  repercussions.2 Its  main  cause
s  constant  and  prolonged  exposure  to  cigarette  smoke  or
ther  noxious  gases  and  particles  which  lead  to  reduced  air
ow  and  pulmonary  hyperinﬂation  due  to  varying  degrees  of
irway  obstruction  and  emphysema,  as  well  as  to  systemic
nﬂammation,  ultimately  causing  skeletal  muscle  dysfunc-
ion,  respiratory  failure,  and  diminished  peripheral  blood
ow.4,24--26
In  patients  with  COPD  and  CVD,  the  interaction  of
athophysiologic  processes  of  the  respiratory,  cardiac  and
ascular  systems  is  complex  and  modulated  by  the  action  of
harmacologic  agents  used  in  the  treatment  of  both  condi-
ions,  some  of  which  have  true  antagonistic  effects  on  the
utonomic  nervous  system.  The  potential  side  effects  associ-
ted  with  the  use  of  these  drugs  to  treat  COPD  may  translate
nto  adverse  events  from  a  cardiovascular  perspective  (and
ice-versa).7,27
The  paradigm  of  the  above  is  the  use  of  BBs  in  the
reatment  of  cardiovascular  diseases  and  beta2-agonists  in
he  treatment  of  respiratory  diseases.7,28--31 The  apparently
pposed  actions  on  sympathetic  tone  modulate  cardio-
ascular  and  respiratory  response  and  will  inadvertently
ave  implications  for  both  systems,  which  is  not  a  contra-
ndication  for  the  optimized  treatment  of  both  pathologies,
s  discussed  in  this  paper.
OPD  effects  on  cardiac  function
oth  diastolic  and  systolic  dysfunction  of  the  right  and
eft  ventricle  seem  to  be  frequent  in  COPD  patients.8,32
irect  compromise  of  right  ventricle  (RV)  is  a  conse-
uence  of  pulmonary  parenchymal  destruction  and  hypoxic
asoconstriction  resulting  in  increased  pulmonary  vascu-18.  https://doi.org/10.1016/j.pulmoe.2018.09.006
ar  resistance.8,32 Right  ventricle  dilation  and  hypertrophy,
s  a  consequence  of  raised  pulmonary  pressure,  can  lead
o  septum  displacement  to  the  left  ventricle,  compromis-
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COPD  and  Cardiovascular  Disease  
ing  left  ventricular  ﬁlling,  stroke  volume  (SV)  and  cardiac
output.33,34
Hypoxia  leads  to  vasodilation  in  systemic  arteries  and
vasoconstriction  in  the  pulmonary  vascular  bed.35 How-
ever,  the  pulmonary  hemodynamic  responses  to  hypoxia  are
quite  variable.35 Chronic  hypoxia  affects  the  pulmonary  vas-
culature  through  both  tonic  vasoconstriction  and  vascular
remodelling  with  miointimal  hyperplasia  of  the  pulmonary
vascular  bed.35
Thus,  in  the  setting  of  CVD,  varying  degrees  of  hypoxia,
lung  hyperinﬂation,  secondary  erythrocytosis,  and  loss  of
pulmonary  vascular  surface  area  all  lead  to  the  inevitable
association  of  CVD  with  varying  degrees  of  pulmonary
hypertension.35
In  addition,  the  left  ventricle  may  be  directly  affected
by  airﬂow  limitation,  but  much  less  is  known  regarding  the
interaction  of  subclinical  lung  function  impairment  with  left
ventricular  function.35,36 Also,  these  underlying  mechanisms
may  be  responsible  for  left  ventricular  failure  symptoms  in
COPD  exacerbations.35,36
Repeated  and  cyclic  increases  in  ventricular  wall  tension
are  thought  to  be  one  of  the  mechanisms  responsible  for
sympathetic  nervous  system  activation  in  these  patients,
perhaps  contributing  to  their  propensity  to  salt  and  water
retention,  as  well  as  the  development  of  systemic  hyper-
tension  and  left  ventricular  hypertrophy.35,36
Some  studies  have  reported  that  a  moderately  reduced
Forced  Expiratory  Volume  in  1  second  (FEV1),  an  indepen-
dent  risk  factor  for  CVD,  is  associated  with  an  increased
incidence  of  HF  in  older37 and  middle-aged  individuals.38,39
Impaired  pulmonary  function  in  young  adulthood  precedes
left  ventricular  dysfunction  later  in  life,40 and  a  linear  asso-
ciation  of  decreasing  FEV1/Forced  Vital  Capacity  (FVC)  ratio
and  increasing  emphysema  (hyperinﬂation)  with  left  ventric-
ular  end-diastolic  volume,  SV  and  cardiac  output  has  been
shown.41,42
Pulmonary  hypertension,  elevated  right  ventricular  ﬁlling
pressure  and  raised  intrathoracic  pressure  are  also  respon-
sible  for  the  higher  incidence  of  atrial  arrhythmias  in  COPD
patients,  probably  due  to  a  dual  effect  of  direct  raised
RV  pressure  and  pro-inﬂammatory  environment  in  COPD
patients.35 The  greater  the  degree  of  RV  dysfunction  at  base-
line,  the  greater  the  hemodynamic  signiﬁcance  of  any  added
vascular  load.35
Chronic  inﬂammation  in  COPD
Besides  classical  pathological  models  based  on  lung  and
systemic  hemodynamics,  there  is  a  growing  evidence  on
the  role  of  the  underlying  local  and  systemic  inﬂammatory
environment.  Chronic  inﬂammation  in  COPD  involves  both
innate  and  adaptive  immunity  and  is  most  pronounced  in
the  bronchial  walls.43 This  inﬂammatory  process  in  COPD
has  a  marked  heterogeneity.  It  results  in  both  emphysema,
with  parenchymal  involvement,  and  chronic  bronchitis,
which  predominantly  affects  the  small  airways.43 Previous
studies  have  found  persistent  chronic  inﬂammatory  fea-Please  cite  this  article  in  press  as:  André  S,  et  al.  Pulmonol.  20
tures  in  16%  of  COPD  patients  and  this  was  associated
with  a  worse  prognosis  with  a  six-times  higher  mortality
compared  to  patients  with  a  pauci-inﬂammatory  proﬁle.44
Once  established,  inﬂammation  in  COPD  is  persistent  and
s
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rogresses  over  time,  despite  elimination  of  smoking  or
ther  environmental  factors.45 Although  the  factors  that
rive  inﬂammation  in  COPD  have  not  been  clearly  estab-
ished,  autoimmunity,  embedded  particles  from  smoking  and
hronic  bacterial  infection  have  all  been  proposed  to  play  a
ole.46
The  inﬂammatory  process  leads  to  an  increase  in  the  tis-
ue  volume  of  the  bronchial  wall,  characterized  by  inﬁltra-
ion  of  the  wall  by  both  innate  (macrophages/neutrophils)
nd  adaptive  inﬂammatory  immune  cells  (CD4,  CD8  and  B
ymphocytes)  with  lymphoid  follicles  formation.  Indeed,  a
ajor  factor  associated  with  lung  inﬂammation  in  COPD
s  autoimmunity.  Lee  et  al  showed  that  emphysema  is  an
utoimmune  disease  characterized  by  the  presence  of  anti-
lastin  antibody  and  T-helper  type  1  (Th1)  responses,  which
orrelate  with  emphysema  severity.47,48
Several  studies  have  highlighted  the  importance  of  the
ung  microbiome  in  lung  disease.49--51 The  most  common
acteria  isolated  from  the  lungs  of  patients  with  COPD
re  non-typeable  Haemophilus  inﬂuenzae  (NTHi).  NTHi  has
een  shown  to  induce  changes  in  COPD  in  an  animal
odel52 and  new  strains  are  also  associated  with  COPD
xacerbations.53 This  agent  has  also  been  shown  to  activate
ung  T  cells  and  cause  the  expression  of  reactive  oxygen
pecies  and  proteases  in  patients  with  COPD.54 The  vicious
ycle  of  inﬂammation-infection  increases  exacerbations.  As
vidence  is  growing  about  these  mechanisms,  efforts  are
eing  made  to  identify  and  deﬁne  clinical  and  analytical
iomarkers  with  prognostic  value.
OPD  and  CVD  biomarkers
n  a  prospective  cohort  study  from  the  Copenhagen  City
eart  Study  (2001-2003)  and  the  Copenhagen  General  Pop-
lation  Study  (2003-2008)  population,  the  role  of  elevated
evels  of  inﬂammatory  biomarkers  in  individuals  with  sta-
le  COPD  as  predictors  of  exacerbations  has  been  studied.55
he  authors  reported  that  concomitant  elevated  levels  of
-reactive  protein  (CRP),  ﬁbrinogen,  and  leukocytes  were
ssociated  with  an  increased  risk  of  frequent  exacerbations
n  individuals  with  stable  COPD.  Compared  to  patients  with
ormal  levels  of  these  biomarkers,  individuals  with  three
levated  inﬂammatory  biomarkers  had  an  approximately
-times  higher  risk  of  having  frequent  exacerbations  dur-
ng  the  ﬁrst  year  of  follow-up.  It  is  not  clear  whether  this
ight  reﬂect  an  underlying  bacterial  colonization  process,
ersistent  latent  viral  infections  in  the  airways  or  a  highly
nﬂammatory  environment.55
The  pathophysiological  mechanisms  and  interaction
etween  COPD  and  cardiac  disease  are  complex,  involv-
ng  multiple  biological  and  immune  mechanisms  modulating
ardiac,  respiratory  and  systemic  effects.55 However,  it  is
ot  possible  to  exactly  ascertain  the  impact  of  each  single
echanism  in  the  whole  process.55
From  a  clinical  perspective,  some  biomarkers  have  been
ested:18.  https://doi.org/10.1016/j.pulmoe.2018.09.006
C-reactive  Protein  is  a  potential  biomarker  of  low  grade
ystemic  inﬂammation  and  atherosclerosis  in  COPD.  The
ecline  in  FEV1/FVC  and  FEV1 is  correlated  with  an  increased
igh-sensitivity  CRP  and  the  risk  of  ischemic  heart  disease  is
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igher  in  patients  with  both  moderate  to  severe  obstruction
nd  higher  CRP  levels.56,57
Fibrinogen  is  an  acute  phase  protein  that  is  has  been
escribed  as  a  marker  of  COPD  activity.  High  levels  of
his  marker  are  a  predictor  of  severity  and  risk  of  COPD
xacerbations.58,59
Brain-type  Natriuretic  Peptide  (BNP)  and  N-terminal
roBNP  (NT-proBNP)  are  early  and  sensitive  biomarkers  for
he  diagnosis  of  HF  associated  with  decreased  left  ventri-
le  ejection  fraction,  left  ventricular  hypertrophy,  increased
eft  ventricle  ﬁlling  pressure,  acute  myocardial  infarction
nd  ischemia.56,60,61 They  are  also  higher  in  patients  with
ulmonary  disorders,  right  ventricular  dysfunction,  pul-
onary  hypertension  and  cor  pulmonale. In  COPD  patients,
he  increase  in  BNP  and  NT-proBNP  is  proportional  to  the
everity  of  right  ventricular  dysfunction.56,60,61 BNP  is  also
igh  in  patients  with  stable  COPD  and  no  pulmonary  hyper-
ension.  In  addition  there  is  a  strong  correlation  between
NP  levels  and  left  ventricular  ejection  fraction  and  sys-
olic  pressure  of  the  pulmonary  artery.56,60,61 Finally,  BNP
evels  have  also  been  associated  to  mortality  risk  in  COPD
atients.56,60,61
Troponin  is  elevated  in  18-27%  of  patients  hospitalized
ue  to  a  COPD  exacerbation  and  is  an  independent  predictor
f  mortality  both  during  the  exacerbation  and  in  the  long
erm.12,62--66
VEGF  (Vascular  Endothelial  Growth  Factor)  is  an  impor-
ant  biomarker  of  prognosis  in  CVD.  VEGF  regulates
ngiogenesis,  promoting  the  migration  and  proliferation  of
ndothelial  cells,  increasing  vascular  permeability  and  mod-
lating  thrombogenicity.  Patients  with  COPD  exacerbations
ave  higher  levels  of  circulating  VEGF.57
Surfactant  protein  D  is  synthesized  and  secreted  by
ronchial  and  alveolar  epithelial  cells  and  can  be  detected  in
uman  plasma.  It  has  a  major  role  in  immune  and  inﬂamma-
ory  regulation  in  the  lung  and  is  also  expressed  in  coronary
rteries,  having  an  anti-inﬂammatory  role.57
OPD and Concomitant CVD assessment
ethods
atients  with  COPD  and  cardiovascular  comorbidity  should
ave  respiratory  function,  cardiac  function,  and  systemic
nﬂammatory  status  assessments.  These  assessments  should
e  conducted  differently  depending  on  whether  a  patient
as  stable  COPD  or  an  acute  exacerbation.
.  For  patients  with  stable  COPD, a  clinical  and  functional
assessment  should  include:
 Complete  clinical  history  and  physical  examination,
including  the  recommended  dyspnea  and  quality  of  life
assessment  questionnaires  modiﬁed  Medical  Research
Council  (mMRC)  and  COPD  Assessment  Test  (CAT).
 Laboratory  assessment  including  complete  blood  count,
arterial  blood  gas  analysis,  CRP,  NT-proBNP  and/or  BNP.
 Spirometry,  static  lung  volumes  and  carbon  monoxide  dif-Please  cite  this  article  in  press  as:  André  S,  et  al.  Pulmonol.  20
fusion  capacity  (DLCO).
 Chest  X-ray.
 12-lead  electrocardiogram  and  further  assessment  with
an  echocardiogram,  if  needed.
•
migure  1  Proposed  evaluation  algorithm  for  CVD  in  stable
OPD.
For  patients  with  known  concomitant  coronary  artery  dis-
ase  or  cardiac  disease,  a  speciﬁc  assessment  should  be
one  according  to  the  current  guidelines,  as  proposed  by
he  authors  --  Figure  1. A  six  minute  walking  test  and  car-
iopulmonary  exercise  testing  are  recommended  if  there  is
o  speciﬁc  contra-indication.
. For  patients  with  cardiac  disease  and  signs/symptoms
or  risk  factors  for  COPD, COPD  should  be  actively
investigated,  so,  in  addition  to  the  clinical  assessment
speciﬁc  for  cardiac  disease,  spirometry,  lung  volumes
and  DLCO  measurements  should  also  be  performed.  Addi-
tional  assessments  should  be  carried  out  according  to  the
results  obtained  from  the  respiratory  and  cardiac  speciﬁc
functional  assessments.
For  both  patients  mentioned  in  A  and  B  sections,  who
requently  undergo  thoracic  CT  scan,  it  is  important  to
eep  in  mind  that  patients  undergoing  evaluation  for  car-
iac  disease,  coronary  angio-CT  may  show  radiologic  signs  of
OPD,  and  COPD  patients  undergoing  thoracic  CT  may  show
oronary  calciﬁcation  or  cardiomegaly  suggesting  underlying
ardiac  disease.67
Due  to  the  multifactorial,  clinical  interactions  and  a
road  spectrum  of  signs  and  symptoms,  there  are  no  speciﬁc
uidelines  for  when  and  how  to  perform  these  functional
ardio-respiratory  assessments.  There  are  broad  rules  that
hould  be  tailored  to  each  individual  patient  according  to
linical  expertise,  and  the  authors  propose  a  speciﬁc  assess-
ent  algorithm  for  CVD  in  stable  COPD  patients  --  Figure  1.
.  For  patients  with  COPD  experiencing  an  acute  exacer-
bation:
 Complete  clinical  history  and  physical  examination.
 Laboratory  assessment  including  complete  blood  count,
leukocyte  count,  platelets,  CRP,  arterial  blood  gas  analy-
sis,  ﬁbrinogen,  NT-proBNP  or  BNP  and  troponin  I.
 Chest  X-ray.18.  https://doi.org/10.1016/j.pulmoe.2018.09.006
 12-lead  electrocardiogram.
The  purpose  is  to  establish  the  main  pathophysiologic
echanisms  underlying  the  acute  exacerbation  when  both
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pathologies  co-exist:  decompensated  cardiac  disease,  COPD
exacerbation,  underlying  infection  or  another  concomitant
diagnosis.  Therapeutic  approach  should  be  driven  accord-
ing  to  the  diagnosis  associated  with  the  acute  clinical
decompensation.  The  treatment  of  these  patients  can  be
quite  challenging,  especially  in  the  acute  setting.  Indeed,
although  the  reason  for  decompensation  can  be  primarily
cardiovascular  or  respiratory  in  nature,  the  authors  propose
that  both  conditions  have  to  be  simultaneously  addressed,
because  of  the  constant  two-way  interaction  of  dysfunc-
tional  mechanisms  --  Figure  2.
COPD and CVD Pharmacological Treatment
The  presence  of  comorbidities  should  not  modify  COPD
treatment  and  comorbidities  should  be  treated  per  usual
standards  regardless  of  the  presence  of  COPD.2
Cardiovascular  drugs  in  COPD  patients
Campo  et  al  conducted  a  review  on  the  safety  and  efﬁ-
cacy  of  cardiovascular  and  respiratory  drugs  in  COPD
patients  with  concomitant  CVD.  Antiplatelet  agents,  antico-
agulants,  angiotensin  converting  enzyme  inhibitors  (ACEi),
angiotensin  receptor  blockers  (ARBs),  and  BBs  are  the  most
commonly  prescribed  drugs  in  patients  with  CVD.68
Antiplatelet  agents  and  anticoagulants
It  is  reasonable  to  think  that  it  might  all  be  useful  in  patients
with  both  COPD  and  CVD  since  thrombocytosis  is  associated
with  increased  mortality  in  COPD.  COPD  patients  submitted
to  percutaneous  coronary  interventions  have  higher  platelet
reactivity,  and  antiplatelet  agents  and  anti-aggregation
therapy  may  act  as  beneﬁcial  in  pulmonary  hypertension  and
in  COPD  patients  at  risk  of  atrial  ﬁbrillation.69--71
According  to  the  available  evidence,  antiplatelet  ther-
apy  has  been  associated  with  a  reduced  1-year  mortality  (ORPlease  cite  this  article  in  press  as:  André  S,  et  al.  Pulmonol.  20
0.63;  95%  CI  0.47--0.85)  in  patients  with  hospital  admission
due  to  acute  exacerbation  of  underlying  COPD.68 Similarly,
Ekstrom  et  al  showed  that  antiplatelet  agents  were  asso-
ciated  with  a  signiﬁcant  reduction  of  mortality  in  COPD
R
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atients  (HR  0.86;  95%  CI  0.75--0.99).30 However,  these  data
re  based  on  post-hoc  analysis  and  no  RCTs  were  conducted
peciﬁcally  on  this  issue.
The  beneﬁt  of  anticoagulant  drugs  relies  on  the
oncomitant  CVD  independently  of  the  COPD  status.68,72
owever,  COPD  seems  to  be  a  risk  factor  for  bleeding
omplications,73,74 namely  in  patients  with  atrial  ﬁbrillation
n  anticoagulant  therapy.75,76
CEi  and  ARBs
mall  clinical  trials  and  observational  studies  have  suggested
n  interaction  between  ACEi  and  FEV1 decline  in  smokers
hilst  others  suggest  a beneﬁt  in  pulmonary  hypertension
n  patients  treated  with  ARBs.68,77,78 However,  there  is  not
ufﬁcient  evidence  to  deﬁne  a  speciﬁc  indication  of  ACEi  or
RBs  in  COPD  patients  other  than  for  the  CVD.68,77,78
Bs
 much  larger  body  of  evidence  and  literature  is  available
bout  indication  and  prescription  of  BBs.  Bronchocon-
triction  from  -blocker  use  is  due  to  antagonism  of
re-junctional  and  post-junctional  -2  receptors,  which
ncovers  cholinergic  tone  resulting  in  airway  constriction.6
iven  this  rationale,  -1  selective  antagonists  potentially
xhibit  a  small  degree  of  dose-related  -2  receptor  block-
de.  A meta-analysis  including  studies  until  2011  concluded
hat  BBs  have  a  positive  effect  in  COPD  patients  with
schemic  heart  disease,  and  cardio-selective  BBs  produce
o  change  in  FEV1 or  respiratory  symptoms,  nor  do  they
ffect  the  FEV1 treatment  response  to  long  acting  -2  ago-
ists  (LABA),  and  it  showed  a  pooled  relative  risk  reduction
n  mortality  for  COPD  patients  receiving  BB  (RR  0.69,  95%  CI
.62--0.78).68,79 A  possible  explanation  for  this  positive  inter-
ction  is  the  protector  effect  of  cardio-selective  BB  against
he  potential  chronotropic,  inotropic  and  pro-arrhythmic
ffects  of  LABA.
Despite  the  safety  of  BBs  in  COPD  patients,  the  treat-
ent  with  BBs  or  ACEi/ARB  was  found  to  be  signiﬁcantly
ower  in  COPD  patients  with  concomitant  HF  than  in  patients
ith  HF  alone.28--30 The  use  of  BBs  has  also  been  reported
o  be  41%  to  58%  lower  than  ACEi/ARB  in  patients  treated
ith  ICS/LABA/LAMA  or  SAMA/SABA.6,68 A  very  recent  review
roposes  that  potential  ways  of  dealing  this  dilemma  of
hether  or  not  to  use  BBs  in  COPD  patients  include  the
evelopment  of  highly  1-selective  -blockers  or  the  use  of
on--blocking  heart  rate  reducing  agents,  such  as  ivabra-
ine,  if  these  are  proven  to  be  beneﬁcial  in  randomised
ontrolled  trials.80
The  authors  conclude  that  the  above  mentioned  drug
lasses  for  COPD  can  be  safely  used  if  concomitant  CVD  is
n  indication.
The  use  of  cardioselective  BBs  in  COPD  patients  seems
o  be  safe  and  may  be  suggested  if  indicated  for  the
VD  per  se.  Cardio-selective  BBs,  if  indicated,  may  be
ecommended  to  COPD  patients,  regardless  of  pulmonary
omorbidity.6,31,68,8118.  https://doi.org/10.1016/j.pulmoe.2018.09.006
espiratory  drugs  in  CVD  patients
ny  bronchodilator  is  potentially  pro-arrhythmic.  Although
ome  studies  report  an  incidence  of  tachydysrythmias  in
 IN+ModelP
6
L
t
d
I
S
c
C
M
c
i
h
t
d
S
a
D
a
r
a
i
c
S
A
r
R
w
S
L
t
a
s
t
p
s
S
I
d
T
u
b
S
M
t
W
h
a
s
w
c
d
P
C
t
e
f
p
u
o
c
p
b
p
i
s
m
d
a
l
i
i
a
o
o
s
m
C
I
c
m
a
a
c
b
c
R
F
F
r
r
t
p
C
S
a
N
N
s
fARTICLEULMOE-1314; No. of Pages 9
 
AMA  treated  COPD  patients,68 the  UPLIFT82 and  TIOSPIR83
rials  did  not  show  an  increased  incidence  of  major  car-
iac  events.  The  cardiovascular  safety  of  LABA,  LAMA,
CS/LABA,  or  LABA/LAMA  therapy  is  well  established.7,10,84--88
peciﬁcally,  a  ﬁxed  once-daily  combination  of  inda-
aterol/glycopyrronium  has  shown  cardiovascular  safety  in
OPD  patients,  with  or  without  comorbid  CVD.23,85,89--91
oreover,  a  very  recent  RCT  has  shown  that  dual  bron-
hodilation  with  indacaterol/glycopyrronium  signiﬁcantly
mproved  cardiac  function  in  patients  with  COPD  and  lung
yperinﬂation.92
Regarding  tachydysrythmias 2 there  is  no  evidence  that
he  COPD  treatment  approach  should  be  changed  due  to  the
iagnosis  of  atrial  ﬁbrillation  or  another  CVD.
peciﬁc  considerations  regarding  short-acting  beta
gonists  (SABAs)
ue  to  their  2-adrenergic  action,  SABAs  may  precipitate
trial  ﬁbrillation  and  hamper  the  control  of  ventricular
esponse,  and  have  the  potential  to  induce  sinus  tachycardia
t  rest  and  dysrhytmias  in  susceptible  patients.93 However,
f  clinically  indicated,  they  should  be  used  as  rescue  medi-
ation.
peciﬁc  considerations  regarding  LABAs
lthough  the  cardiovascular  safety  of  LABAs  in  COPD  patients
emains  a  controversial  issue,  a  recent  meta-analysis  of  24
CTs  concluded  that  it  is  safe  to  use  LABAs  in  COPD  patients
ith  CV  comorbidities.87
peciﬁc  considerations  regarding  LAMAs
AMAs  are  safe  within  a  wide  range  of  doses  and  clinical  con-
exts.  Some  concerns  have  been  raised  regarding  tiotropium
dministration  via  the  Respimat® device,  but  the  TIOSPIR
tudy  showed  it  to  be  as  safe  as  tiotropium  administred  via
he  Handihaler®.  Glycopyrronium  also  has  a  favorable  safety
roﬁle  with  no  increase  in  CV  risk.  The  safety  proﬁle  is  very
imilar  amongst  the  different  LAMAs.2,79,88,94,95
peciﬁc  considerations  regarding  ICS
CS  are  not  used  as  monotherapy  in  COPD  patients.  ICS  safety
ata  are  less  robust  than  safety  data  on  bronchodilators.
here  is  no  unequivocal  evidence  regarding  safety  of  ICS
sed  as  combination  therapy  on  COPD  patients  with  comor-
id  CVD.7,79,88
peciﬁc  considerations  regarding  methylxanthines
ethylxanthines  have  a  narrow  therapeutic  window  and
heir  toxicity  is  well  established  and  dose-dependent.
ith  regard  to  CVD,  their  pro-arrhythmic  effect  should  be
ighlighted.  There  is  also  a  potential  pharmacokinetic  inter-
ction  with  warfarin  and  digoxin.2 Theophylline  has  been
uggested  to  have  an  anti-inﬂammatory  effect  in  patientsPlease  cite  this  article  in  press  as:  André  S,  et  al.  Pulmonol.  20
ith  COPD.96
In  conclusion,  ICS,  LABAs,  LAMAs  and  associations  can  be
onsidered  safe  in  COPD  patients  with  concomitant  cardiac
isease.
A
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rognostic Implications
OPD  patients  with  concomitant  CVD  have  a worse  prognosis
han  simply  the  sum  of  the  prognosis  of  each  disease.  How-
ver,  it  is  difﬁcult  to  establish  a  hazard  ratio  or  risk  ratio
or  a  speciﬁc  patient  or  group  of  patients,  due  to  the  com-
lex  etiologic  and  pathophysiologic  interaction  network  that
nderlies  both  diseases.20,23 Much  of  the  literature  relies
n  epidemiology  data  and  management  of  cardiovascular
omorbidities  in  COPD.  Much  less  is  described  regarding  the
rognostic  implications  of  different  cardiovascular  comor-
idities  in  COPD  patients  and  even  less  in  subgroups  of  COPD
atients,  both  according  to  GOLD  stages  and  age.
Summarizing  the  literature,  the  risk  of  CVD  in  COPD
s  two  to  three-fold  greater  than  the  risk  associated  with
moking.97 COPD  is  also  independently  associated  with
eaningful  cardiovascular  events.98 FEV1 is  an  indepen-
ent  risk  factor  for  cardiovascular  disease  regardless  of
ge,  gender,  tobacco  addiction,  cholesterol,  and  education
evel/social  class.98 Reduced  pulmonary  function  in  COPD
s  associated  with  increased  incidence  of  all-cause  mortal-
ty,  cardiovascular-related  mortality,  myocardial  infarction
nd  arrhythmias.99 In  the  TORCH  trial,  cardiovascular  deaths
ccurred  in  26%  of  patients,14 and  in  the  UPLIFT  trial  in  18.8%
f  patients.100 Both  trials  included  patients  with  moderate  to
evere  COPD.  Cardiovascular  death  remains  the  most  com-
on  cause  of  mortality  in  COPD  patients.101
onclusions
n  conclusion,  the  identiﬁcation  and  proper  treatment  of
ardiac  comorbidity  is  a  very  important  measure  in  the
anagement  of  COPD,  as  prognosis  in  COPD  is  greatly
ffected  by  the  presence  of  CVD.  Due  to  pathophysiological
nd  inﬂammatory  interactions  between  COPD  and  cardiovas-
ular  disease,  the  presence  of  cardiac  comorbidities  should
e  actively  investigated  in  all  COPD  patients,  both  in  stable
onditions  and  in  the  context  of  exacerbations.
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